TCGA-44-6774-01A-21R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.690
- ANGIOGENESIS+0.580
- TGF_BETA_SIGNALING+0.550
- HEDGEHOG_SIGNALING+0.490
- UV_RESPONSE_DN+0.470
- APICAL_JUNCTION+0.400
- INFLAMMATORY_RESPONSE+0.390
- COAGULATION+0.380
- IL6_JAK_STAT3_SIGNALING+0.380
- KRAS_SIGNALING_UP+0.380
Top 10 suppressed
- E2F_TARGETS-0.510
- MYC_TARGETS_V1-0.500
- OXIDATIVE_PHOSPHORYLATION-0.490
- MYC_TARGETS_V2-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- DNA_REPAIR-0.420
- G2M_CHECKPOINT-0.390
- MTORC1_SIGNALING-0.330
- FATTY_ACID_METABOLISM-0.310
- P53_PATHWAY-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1b5aacb8-0e2e-4888-bc61-48c4aa4d4684 | — | — | 0.938 |
| 2 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.932 |
| 3 | cdb7b56c-ddca-4596-bfa2-6823c12837e2 | — | — | 0.925 |
| 4 | TCGA-85-6175-01A-11R-1820-07 | — | cohortSQ1 | 0.920 |
| 5 | TCGA-CV-7435-01A-11R-2132-07 | — | — | 0.916 |
| 6 | TCGA-77-8008-01A-21R-2187-07 | — | cohortSQ1 | 0.913 |
| 7 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.912 |
| 8 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.912 |
| 9 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.908 |
| 10 | 67ed15bc-bbe5-4da7-81f9-002c54483f67 | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.690 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.550 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.490 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.470 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |